Investigational drug · Phase 3
EP-088_MM09
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "EP-088_MM09"
First trial start
2026
Feb 24, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EP-088_MM09", any sponsor or status.
Conditions studied
As listed on its trial records.
- Allergic Rhinitis
- Allergic Rhinoconjunctivitis
- Allergic Asthma
Approved drugs for the same conditions: Asthma · Allergies (allergic rhinitis) · Respiratory · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "EP-088_MM09" as an intervention, largest first.
- Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063.Pivotal-lookingRecruiting
Inmunotek S.L.Industry
NCT07904052 · 250 participants (planned) · Start Feb 24, 2026 · Primary completion Jul 2029
Drug: EP-088_MM09; Placebo · For: Allergic Rhinitis; Allergic Rhinoconjunctivitis; Allergic Asthma
Sites: Coimbra, Portugal; Lisbon, Portugal; Porto, Portugal · 16 sites in all
- Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-069.Pivotal-lookingRecruiting
Inmunotek S.L.Industry
NCT07904195 · 250 participants (planned) · Start Apr 15, 2026 · Primary completion Jul 2029
Drug: EP-088_MM09; Placebo · For: Allergic Rhinitis; Allergic Rhinoconjunctivitis; Allergic Asthma
Sites: Covilha, Portugal; Portimão, Portugal; Ponta Delgada, Portugal · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Allergic Rhinitis
- GR1802Phase 34 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Allergic Rhinitis, Seasonal, Allergic Rhinitis, Chronic Rhinosinusitis With Nasal Polyps
- 000 MM09Phase 32 trials
Inmunotek S.L. · Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- DEP114Phase 32 trials
EMS · Persistent Allergic Rhinitis, Allergic Rhinitis
- INI-2004Phase 21 trial
Inimmune Corporation · Allergic Rhinitis Due to Allergens, Rhinitis Allergic, Allergic Rhinitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.